Zhitong Financial APP learned that more studies have proved that the existing COVID-19 vaccine is effective against Omicron variants, and some anti-epidemic units rose against the market on Monday. At the close of trading on Monday, BioNTech (BNTX.US) rose 7.97%, Pfizer Inc (PEF.US) rose 4.59%, BioNTech (MRNA.US) rose 5.81%, and AstraZeneca PLC (AZN.US) rose 1.04%.

It is reported that an Israeli study of 40 participants over the weekend found that people who received a booster injection of Pfizer Inc / BioNTech COVID-19 vaccine significantly increased their levels of antibodies against the Omicron variant. Pfizer Inc and BioNTech also issued a statement last week that their three-dose course of COVID-19 vaccine could neutralize the Omicron variant in laboratory tests.

At the same time, a study from the University of Oxford found that the Omicron variant weakened the protective efficacy provided by the first two doses of the vaccines provided by Pfizer Inc and AstraZeneca PLC, but this did not indicate that the Omicron variant was more likely to cause severe illness or death; in addition, the study also showed that strengthening needles could increase the protective effect against the Omicron variety to some extent.